Novavax: stock boosted by EUA for Covid-19 vaccine in India
(CercleFinance.com) - Novavax has announced that the Drug Controller General of India (DCGI) has granted an Emergency Use Authorisation (EUA) for its Covid-19 vaccine, which will be manufactured and marketed in India by Serum Institute of India (SII) under the brand name Covovax.
Novavax/SII vaccine has recently received EUA approval in Indonesia and the Philippines, as well as conditional marketing authorisation from the European Commission. It will be marketed in the European Union under the name Nuvaxovid.
Novavax has also announced regulatory filings for its vaccine in several countries worldwide, including South Korea and Japan through its local partners. Novavax plans to submit the complete dossier to the US FDA by the end of the year.
The share is up 10% on this news today.
Copyright (c) 2021 CercleFinance.com. All rights reserved.